The changing cost of breast cancer care: lessons from a centralised modern cancer centre.


Journal

Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864

Informations de publication

Date de publication:
May 2019
Historique:
received: 24 07 2017
accepted: 16 07 2018
pubmed: 23 7 2018
medline: 18 6 2019
entrez: 23 7 2018
Statut: ppublish

Résumé

The cost of new cancer technologies has been the subject of intense debate in recent years. There have been significant advances in therapeutic techniques for breast cancer over the past 20 years. This has been accompanied by the concentration of services in designated cancer centres. The aim of this study was to examine the changing cost of breast cancer management over an 18-year period and identify factors underlying this. We use breast cancer services data from Galway University Hospital in 1995-1996, 2005-2006 and 2011-2012 to examine the changing pattern of care costs and survival. The number of patients treated for breast cancer rose from 200 in 1995-1996, to 411 in 2005-2006 and 563 in 2011-2012. Two-year survival rose in line with national figures from 84 to 89.78 and 92.07%, in the three-time periods respectively. Adjusting for inflation, the average cost per patient rose from €14,710 (95% C.I., €13,398 to €16,022) in 1995-1996 to €30,405 (95% C.I., €38,620 to €32,189) in 2005-2006, before falling to €14,458 (C.I., €13,343 to €15,572) in 2011-2012. We found significant changes in the pattern of costs, with some rising in relative and absolute terms while others fell as new therapies became available and/or moved off patent. Within an evolving context where services are centralised, new therapies emerge and subsequently come off patent, our understanding of the value of cancer therapies continues to evolve. This has important implications for the evaluation of new therapies and broader policy initiatives in this area.

Sections du résumé

BACKGROUND BACKGROUND
The cost of new cancer technologies has been the subject of intense debate in recent years. There have been significant advances in therapeutic techniques for breast cancer over the past 20 years. This has been accompanied by the concentration of services in designated cancer centres. The aim of this study was to examine the changing cost of breast cancer management over an 18-year period and identify factors underlying this.
METHODS METHODS
We use breast cancer services data from Galway University Hospital in 1995-1996, 2005-2006 and 2011-2012 to examine the changing pattern of care costs and survival.
RESULTS RESULTS
The number of patients treated for breast cancer rose from 200 in 1995-1996, to 411 in 2005-2006 and 563 in 2011-2012. Two-year survival rose in line with national figures from 84 to 89.78 and 92.07%, in the three-time periods respectively. Adjusting for inflation, the average cost per patient rose from €14,710 (95% C.I., €13,398 to €16,022) in 1995-1996 to €30,405 (95% C.I., €38,620 to €32,189) in 2005-2006, before falling to €14,458 (C.I., €13,343 to €15,572) in 2011-2012. We found significant changes in the pattern of costs, with some rising in relative and absolute terms while others fell as new therapies became available and/or moved off patent.
CONCLUSION CONCLUSIONS
Within an evolving context where services are centralised, new therapies emerge and subsequently come off patent, our understanding of the value of cancer therapies continues to evolve. This has important implications for the evaluation of new therapies and broader policy initiatives in this area.

Identifiants

pubmed: 30032478
doi: 10.1007/s11845-018-1872-4
pii: 10.1007/s11845-018-1872-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-414

Références

Demography. 1999 Nov;36(4):475-95
pubmed: 10604076
Br J Cancer. 2006 Jan 16;94(1):36-42
pubmed: 16333307
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8
pubmed: 19564563
J Health Econ. 2010 May;29(3):333-46
pubmed: 20363520
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Blood. 2013 May 30;121(22):4439-42
pubmed: 23620577
Breast Cancer (Dove Med Press). 2013 Aug 30;5:79-85
pubmed: 24648761
Health Aff (Millwood). 2014 Oct;33(10):1801-4
pubmed: 25288425
Health Aff (Millwood). 2015 Apr;34(4):555-61
pubmed: 25847636
Health Aff (Millwood). 2015 Apr;34(4):562-70
pubmed: 25847637
Lancet Oncol. 2016 Jan;17(1):39-47
pubmed: 26670089
Health Serv Res. 2018 Feb;53(1):175-196
pubmed: 27873305

Auteurs

Doireann P Joyce (DP)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland. doireann.joyce@gmail.com.

Ciaran O'Neill (C)

J.E. Cairnes School of Business & Economics, National University of Ireland Galway, Galway, Ireland.

Helen M Heneghan (HM)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Catherine Curran (C)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Kevin Barry (K)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Karl Sweeney (K)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Carmel Malone (C)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Ray McLaughlin (R)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Michael J Kerin (MJ)

Discipline of Surgery, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH